URL has been copied successfully!
Good morning. As I’ve been watching the NBA finals, every commercial break has started to sound like this.
GSK buys maker of targeted cancer drugs for $10.6B
Nuvalent is the latest biotech to be subsumed in the recent wave of pharma acquisitions, my colleague Andrew Joseph reported this morning. The company has two drugs under review by the Food and Drug Administration that target genetic mutations found in lung cancer. Approval decisions on both are expected later this year.
Please follow us:
